These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23830806)

  • 1. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):30-41. PubMed ID: 23830806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Future Oncol; 2015; 11(21):2949-61. PubMed ID: 26422782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
    Shameem R; Hamid MS; Wu S
    Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
    Schutz FA; Je Y; Choueiri TK
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
    Zhou JX; Feng LJ; Zhang X
    Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.
    Ramirez-Fort MK; Case EC; Rosen AC; Cerci FB; Wu S; Lacouture ME
    Am J Clin Oncol; 2014 Jun; 37(3):266-71. PubMed ID: 23241507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis.
    Abdel-Rahman O; Fouad M
    Future Oncol; 2015; 11(1):79-90. PubMed ID: 25572784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):477-86. PubMed ID: 25665062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-induced hematologic changes in patients with metastatic breast cancer.
    Chen A; Chen L; Al-Qaisi A; Romond E; Awasthi M; Kadamyan-Melkumyan V; Massarweh S
    Clin Breast Cancer; 2015 Feb; 15(1):48-53. PubMed ID: 25199576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
    Peng L; Zhou Y; Ye X; Zhao Q
    Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
    Qi WX; Huang YJ; Yao Y; Shen Z; Min DL
    PLoS One; 2013; 8(6):e65166. PubMed ID: 23785409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015; 15(7):847-58. PubMed ID: 25994247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R; Lacouture M; Wu S
    Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1529-36. PubMed ID: 25159115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.
    Sui JD; Wang Y; Wan Y; Wu YZ
    Drug Des Devel Ther; 2018; 12():1645-1657. PubMed ID: 29922039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology.
    Ravaud A; Urva SR; Grosch K; Cheung WK; Anak O; Sellami DB
    Eur J Cancer; 2014 Feb; 50(3):486-95. PubMed ID: 24332451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
    Shameem R; Lacouture M; Wu S
    Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
    Garcia CA; Wu S
    Cancer Invest; 2016 Nov; 34(10):521-530. PubMed ID: 27791402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.